Home › Linfoma di Burkitt › Michigan
Studi clinici su Linfoma di Burkitt nello stato di Michigan
10 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Michigan.
Città nello stato di Michigan
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- e altri 1
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- e altri 22
In reclutamentoFase 3
Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- e altri 20
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
In reclutamentoFase 1/2
6 Months – 25 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
- e altri 1
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- e altri 2
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- C.S. Mott University of Michigan, Ann Arbor
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
- University of Michigan Rogel Cancer Center, Ann Arbor
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 lug 2026 · NCT07532525The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids
In reclutamentoFase 2
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 mag 2025 · NCT03509961Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.